Document Type

Editorial

Publication Date

2026

DOI

10.21873/anticanres.18162

Publication Title

Anticancer Research

Volume

46

Issue

5

Pages

2829

Abstract

[Introduction] As the guest editor of the Special Issue on Ovarian Cancer Immunology Immunotherapy, I would like to include certain brief comments on the current state of the field and to introduce the Special Issue. Ovarian carcinoma and malignant melanoma are the first human tumors where immune responses, primarily restricted to autologous tumor cells, were first demonstrated. T-cell lines and clones developed in recombinant interleukin-2 (rIL-2) from tumor-infiltrating lymphocytes (TIL) from these tumors exhibited cytotoxicity and/or cytokine production, primarily restricted to autologous tumor cells. The T-cell receptor (TCR) and the CD3 differentiation antigen on effector T cells and HLA on target tumor cells, are critical molecules of the T-cell anti-tumor responses. Subsequent studies demonstrated that peptides, derived from tumor antigens and presented to T cells by self-HLA are recognized. These anti-tumor T cell responses are trimolecular complex (TCR/peptide/HLA) immune responses.

Rights

© 2026 The Authors.   This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Original Publication Citation

Platsoucas, C. D. (2026). Ovarian carcer immunology and immunotherapy: Editorial note. Anticancer Research, 46(5), Article 2829. https://doi.org/10.21873/anticanres.18162

ORCID

0009-0003-7283-0804 (Platsoucas)

Download

Share

 
COinS